[beta2-Microglobulin in cancer patients (author's transl)].
Cancerembryonic antigen (CEA) and beta2-microglobulin (beta2m) have been measured in cancer patients and patients with benign diseases. Of 168 patients with intestinal cancer, almost 90% had increasing concentrations of either CEA or beta2m or both. In 29 patients at different stages of pancreatic cancer there was a high incidence of increased values in the more severe cases. In 60 patients with histologically classified colorectal cancer the TNomegaMomega group of 19 patients had 47% and 42% of elevated beta2m and CEA respectively. A significant correlation of beta2m or CEA to extension of disease was noted. In benign intestinal disease like cirrhosis and pancreatitis both beta2m and CEA is commonly elevated. Of 26 breast cancer patients, seven had elevated CEA and five had elevated beta2m values before treatment. In the patients with extraganglionary metastasis almost 90% had high beta2m or CEA or both. Of 40 patients with uterine cancer, 26 were found to have increased values of beta2m or CEA or both. Finally, 140 colorectal cancer patients, 62 patients with breast cancer and 10 patients with uterine cancer have been followed longitudinally.
D001609:Beta-Globulins / Q000032:analysis*; D001943:Breast Neoplasms / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000276:immunology; D008103:Liver Cirrhosis / Q000276:immunology; D008137:Longitudinal Studies; D009369:Neoplasms / Q000276:immunology*; D010190:Pancreatic Neoplasms / Q000276:immunology; D010195:Pancreatitis / Q000276:immunology; D014594:Uterine Neoplasms / Q000276:immunology; D001613:beta 2-Microglobulin / Q000032:analysis*
D001609:Beta-Globulins; D002272:Carcinoembryonic Antigen; D001613:beta 2-Microglobulin
La beta2-Microglobulineen pathologie cancéreuse.